Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
about
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGDImmunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human non-small cell lung cancer cells in vitro and in vivoSecond-line chemotherapy for non-small cell lung cancer.Innovative treatments for non-small cell lung cancer.Taxanes for advanced non-small cell lung cancer.A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic CancerSecond-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.Grape seeds: ripe for cancer chemoprevention.Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression.Grape seed proanthocyanidins inhibit cigarette smoke condensate-induced lung cancer cell migration through inhibition of NADPH oxidase and reduction in the binding of p22(phox) and p47(phox) proteins.Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.
P2860
Q28548244-1B89A8B2-B378-400A-8A8C-055FE718C00FQ33960866-0E52521F-692C-440E-B450-5CAB3B91FBB9Q34075693-7C15C417-0087-4826-8D1F-131BCDE6BD9AQ34424790-F75EFA58-6D1D-424F-9ED8-4CDB7134FA7AQ34481453-8D843EFD-5737-435E-A7C0-C73015EC1E62Q35020524-EDF717FF-4B3E-4D42-98ED-B0274BA5CCAAQ36153450-031EB629-735D-4061-83D3-8EE596FF3E03Q36615385-2A0BE9CD-80A4-4F5E-A348-F6536ECA9ADBQ36695419-F4A8995C-9520-4127-8D27-AB89A54614FBQ37010010-21B88456-7DD2-4FFD-B902-2B23B11F80B1Q37077398-D8C7F9A0-8C89-4C0A-978E-C7C3D320A36BQ38998253-510DBC30-E4C1-462A-8EE5-5B7823E85987Q43260835-E7F3EB2B-D8AE-47B4-82F8-67830CD838C9Q45114042-E6D55230-BC33-48FA-ACF4-4E16CEE35A2F
P2860
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Second-line chemotherapy for r ...... new agents make a difference?
@ast
Second-line chemotherapy for r ...... new agents make a difference?
@en
Second-line chemotherapy for r ...... new agents make a difference?
@nl
type
label
Second-line chemotherapy for r ...... new agents make a difference?
@ast
Second-line chemotherapy for r ...... new agents make a difference?
@en
Second-line chemotherapy for r ...... new agents make a difference?
@nl
prefLabel
Second-line chemotherapy for r ...... new agents make a difference?
@ast
Second-line chemotherapy for r ...... new agents make a difference?
@en
Second-line chemotherapy for r ...... new agents make a difference?
@nl
P1433
P1476
Second-line chemotherapy for r ...... new agents make a difference?
@en
P2093
D Ferrigno
G Buccheri
P304
P356
10.1016/S0169-5002(00)00112-4
P577
2000-08-01T00:00:00Z